Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC.GLYC · Entity 5255 | SVP, Chief Business Officer | November 11, 2022 | November 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRESCENT BIOPHARMA, INC.
Report date November 11, 2022 · Filed November 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,161 |
Reported balance
After 2022-11-11 transaction · row 1
1 source rowRow 1 · 2022-11-11 · Purchase · Acquired 6,500 · Balance 29,161 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 11, 2022 Filed Nov 14, 2022 21:04 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | PurchaseCommon Stock | 6,500 | $1.05 | $6,825.00 |
DisclosureSEC source: 0001209191-22-056563 · doc4.xml · nonDerivative · entry 1 Girard Armand · CIK 0001769636 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,161 Read SEC document |
| March 09, 2022 Filed Mar 10, 2022 22:05 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | SaleCommon Stock | 2,339 | $1.09 | $2,549.51 |
DisclosureSEC source: 0001209191-22-017968 · doc4.xml · nonDerivative · entry 1 Girard Armand · CIK 0001769636 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,661 F1 · kind: The sales reported on this Form 4 were effected to satisfy tax withholding obligations in connection with the settlement of restricted stock units as part of a "sell to cover" transaction and do not represent discretionary trades by the reporting person. F2 · price: The common stock was sold by the reporting person in a series of open market transactions on the transaction date with a volume weighted average sale price of $1.09. The range of sales prices for the transactions reported was $1.09 to $1.11 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 21, 2022 Filed Jan 26, 2022 02:02 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 47,700 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-22-004896 · doc4.xml · derivative · entry 2 Girard Armand · CIK 0001769636 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,700 Underlying: Common Stock · 47,700 shares Expires 2032-01-20 F2 · derivative.exercise_date: 50% of the shares underlying this option will vest upon FDA approval of the Issuer's product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remainder will vest upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| January 21, 2022 Filed Jan 26, 2022 02:02 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 144,700 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-22-004896 · doc4.xml · derivative · entry 1 Girard Armand · CIK 0001769636 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,700 Underlying: Common Stock · 144,700 shares Expires 2032-01-20 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 21, 2023 and the remaining underlying shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:07 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001209191-21-004850 · doc4.xml · derivative · entry 2 Girard Armand · CIK 0001769636 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-01-19 F3 · derivative.exercise_date: 25% of the shares underlying this option vest on January 20, 2022 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 21:07 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004850 · doc4.xml · nonDerivative · entry 1 Girard Armand · CIK 0001769636 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: 25% of these restricted stock units vest on each of January 20, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 21:23 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001209191-20-004828 · doc4.xml · derivative · entry 1 Girard Armand · CIK 0001769636 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-01-21 F1 · derivative.exercise_date: One-fourth of the shares underlying this option vest on January 22, 2021 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.